These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11034276)

  • 21. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010).
    Cantón R; Loza E; Aznar J; Calvo J; Cercenado E; Cisterna R; Romo FG; Hontangas JL; Calvo CR; Barrenechea AI; Tubau F; Weber I; Yuste P; Cavanillas R;
    Rev Esp Quimioter; 2011 Dec; 24(4):223-32. PubMed ID: 22173194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular basis of β-lactamase production in Gram-negative bacteria from Saudi Arabia.
    Yezli S; Shibl AM; Memish ZA
    J Med Microbiol; 2015 Feb; 64(Pt 2):127-136. PubMed ID: 25418734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of extended spectrum beta lactamase mediated resistance in neonatal septicemia.
    Vinodkumar CS; Neelagund YF
    Indian J Pathol Microbiol; 2006 Oct; 49(4):616-9. PubMed ID: 17183878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended broad spectrum beta-lactamase in Klebsiella pneumoniae including resistance to cephamycins.
    Bauernfeind A; Chong Y; Schweighart S
    Infection; 1989; 17(5):316-21. PubMed ID: 2689349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. beta-Lactam susceptibility patterns and investigation of cephalosporin hydrolysing beta-lactamases of Gram-negative extraintestinal clinical isolates.
    Gál Z; Szabó D; Kovács P; Hernádi F; Tóth-Martinez B; Rozgonyi F
    Int J Antimicrob Agents; 2000 Dec; 16(4):395-400. PubMed ID: 11118847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the effectiveness of three different cephalosporin/clavulanate combinations for the phenotypic confirmation of extended-spectrum beta-lactamase producing bacteria isolated from urine samples at National Public Health Laboratory, Kathmandu, Nepal.
    Bhandari R; Pant ND; Poudel A; Sharma M
    BMC Res Notes; 2016 Aug; 9():390. PubMed ID: 27488224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
    Bradford PA
    Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution and spread of SHV extended-spectrum beta-lactamases in gram-negative bacteria.
    Heritage J; M'Zali FH; Gascoyne-Binzi D; Hawkey PM
    J Antimicrob Chemother; 1999 Sep; 44(3):309-18. PubMed ID: 10511397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
    Boyle DP; Zembower TR
    Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
    Livermore DM; Mushtaq S; Nguyen T; Warner M
    Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.
    Schito GC; Pesce A; Debbia EA
    Drugs; 1994; 47 Suppl 3():1-8; discussion 8-9. PubMed ID: 7518761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemic and endemic spread of Klebsiella pneumoniae producing SHV-5 beta-lactamase in Dubrava University Hospital, Zagreb, Croatia.
    Bedenić B; Schmidt H; Herold S; Monaco M; Plecko V; Kalenić S; Katíc S; Skrlin-Subić J
    J Chemother; 2005 Aug; 17(4):367-75. PubMed ID: 16167514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
    Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
    J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence and prevalence of beta-lactamase-producing Klebsiella pneumoniae resistant to cephems in Japan.
    Muratani T; Kobayashi T; Matsumoto T
    Int J Antimicrob Agents; 2006 Jun; 27(6):491-9. PubMed ID: 16701983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic research to overcome newly emerged multidrug-resistant bacteria.
    Arakawa Y
    Microbiol Immunol; 2020 Apr; 64(4):231-251. PubMed ID: 32068266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin.
    Riedel S; Huband MD; Sader HS; Flamm RK; Jones RN
    J Clin Microbiol; 2017 Oct; 55(10):3130-3134. PubMed ID: 28794180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining an extended-spectrum beta-lactamase.
    Livermore DM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():3-10. PubMed ID: 18154524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.